Discretionary Appellate Review of Non-Final Orders: It’s Time to Change the Rules

This article discusses the uncertainty of United States Courts of Appeals jurisdiction over non-final orders

EVALUATING CLINICAL MASTITIS IN DAIRY CATTLE FED MONENSIN

The effect of Monensin on clinical mastitis in dairy cattle was evaluated from data collected at nine geographical clinical field trials using 966 Holstein cows and heifers in the United States and Canada. At each site, a randomized complete block design was conducted. Monensin (Rumensin®) was fed at concentrations of 0, 8, 16, or 24 ppm in a total mixed ration beginning 21 days before first calving for all nine sites, up to 7 days after second calving for six sites, and 203 days after second calving for three sites. Quarter milk samples were taken and cultured to determine the causative pathogen for each mastitis case and if clinical signs were observed the disease data were grouped according to etiology and analyses conducted. Analyses were conducted for all clinical mastitis cases as well as for a breakdown of the clinical mastitis cases into microorganism group levels. A generalized linear mixed model and a linear mixed model were used to determine if there were significant differences in clinical mastitis between the non-zero concentrations of Monensin and controls. Response variables for the clinical mastitis cases that were analyzed using a generalized linear mixed model were Animal rate, Quarter rate, Observation rate, and Incident rate. An additional response variable, Average case duration, was analyzed using a linear mixed model. Inferences from the analyses indicate that Monensin does not influence the susceptibility of dairy cattle to clinical mastitis

THE EFFECT OF MONENSIN ON LACTATION DAIRY COWS: A DOSE RESPONSE EVALUATION

Monensin (Rumensin®) was fed at doses of 0, 8, 16, or 24 ppm to 966 dairy cows in nine different geographical locations in the USA and Canada. A dose response analysis was conducted on the primary variable, milk production efficiency, to determine the most appropriate dose response function, establish a minimum effective dose, and, when possible, determine a maximum effective dose. Linear mixed models (SAS® Proc Mixed v6.12) were fit to the data. Linear contrasts comparing the non-zero doses of monensin to the control were done to initially determine a minimum effective dose from the 3 non-zero design points. In addition, eight predefined linear contrasts were used to initially determine the general linear-plateau shape of a dose response function for each primary variable. A weighted regression analysis of the least squares means and corresponding standard errors was used when it was necessary to discriminate between the competing linear-plateau functions. A non-overlapping confidence interval process was followed, if it was deemed appropriate, to establish a minimum effective dose for a nondesign point. In cases where the dose response function had a plateau, the dose where the plateau began was classified as the “maximum effective dose” (minimum dose for maximum effect). In cases where the dose response function did not have a plateau, the maximum effective dose was the largest dose used in the study if the response rate was significant

INTERDEPENDENT INFRASTRUCTURE RESILIENCE IN THE U.S. VIRGIN ISLANDS: PRELIMINARY ASSESSMENT

Prepared for: Federal Emergency Management AgencyThe U.S. Virgin Islands (USVI) is a territory comprised of three main islands—Saint Croix, Saint John, and Saint Thomas—and a number of smaller surrounding islands, located in the Leeward Islands of the Lesser Antilles approximately 40 miles east of Puerto Rico and over 1,100 miles from Miami, Florida. In September 2017, two Category-5 hurricanes made landfall within a two-week period and collectively devastated the homes, businesses, and infrastructure throughout the Territory.This technical report (1) explains the structure, function, and tensions associated with energy, water, transportation, and communication infrastructure that were chronic problems prior to the hurricanes; (2) documents hurricane response, recovery, and mitigation activities for these infrastructure systems after the hurricanes; and (3) provides concrete approaches to overcome potential barriers to resilience (where they exist) and open questions for research (where they do not yet exist).Federal Emergency Management AgencyFederal Emergency Management AgencyApproved for public release; distribution is unlimited

Survival-Time Distribution for Inelastic Collapse

In a recent publication [PRL {\bf 81}, 1142 (1998)] it was argued that a randomly forced particle which collides inelastically with a boundary can undergo inelastic collapse and come to rest in a finite time. Here we discuss the survival probability for the inelastic collapse transition. It is found that the collapse-time distribution behaves asymptotically as a power-law in time, and that the exponent governing this decay is non-universal. An approximate calculation of the collapse-time exponent confirms this behaviour and shows how inelastic collapse can be viewed as a generalised persistence phenomenon.Comment: 4 pages, RevTe

Exposure to Bisphenol A and Other Phenols in Neonatal Intensive Care Unit Premature Infants

Objective: We previously demonstrated that exposure to polyvinyl chloride plastic medical devices containing di(2-ethylhexyl) phthalate (DEHP) was associated with higher urinary concentrations of several DEHP metabolites in 54 premature infants in two neonatal intensive care units than in the general population. For 42 of these infants, we evaluated urinary concentrations of several phenols, including bisphenol A (BPA), in association with the use of the same medical devices. Measurements: We measured the urinary concentrations of free and total (free plus conjugated) species of BPA, triclosan, benzophenone-3, methyl paraben, and propyl paraben. Results: The percentage of BPA present as its conjugated species was > 90% in more than three-quarters of the premature infants. Intensity of use of products containing DEHP was strongly associated with BPA total concentrations but not with any other phenol. Adjusting for institution and sex, BPA total concentrations among infants in the group of high use of DEHP-containing products were 8.75 times as high as among infants in the low use group (p < 0.0001). Similarly, after adjusting for sex and DEHP-containing product use category, BPA total concentrations among infants in Institution A were 16.6 times as high as those among infants in Institution B (p < 0.0001). Conclusion: BPA geometric mean urinary concentration (30.3 μg/L) among premature infants undergoing intensive therapeutic medical interventions was one order of magnitude higher than that among the general population. Conjugated species were the primary urinary metabolites of BPA, suggesting that premature infants have some capacity to metabolize BPA. The differences in exposure to BPA by intensity of use of DEHP-containing medical products highlight the need for further studies to determine the specific source(s) of exposure to BPA

Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial

BACKGROUND: A previous analysis of the placebo arm of the Prostate Cancer Prevention Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified a link between inflammation and higher-grade prostate cancer and serum PSA. Here we studied these associations in the PCPT finasteride arm. METHODS: Prostate cancer cases (N=197) detected either on a clinically indicated biopsy or on protocol-directed end-of-study biopsy, and frequency-matched controls (N=248) with no cancer on an end-of-study biopsy were sampled from the finasteride arm. Inflammation in benign prostate tissue was visually assessed using digital images of H&E stained sections. Logistic regression was used for statistical analysis. RESULTS: In the finasteride arm, 91.6% of prostate cancer cases and 92.4% of controls had at least one biopsy core with inflammation in benign areas; p < 0.001 for difference compared to placebo arm. Overall, the odds of prostate cancer did not differ by prevalence (OR=0.90, 95% CI 0.44-1.84) or extent (P-trend=0.68) of inflammation. Inflammation was not associated with higher-grade disease (prevalence: OR=1.07, 95% CI 0.43-2.69). Furthermore, mean PSA concentration did not differ by the prevalence or extent of inflammationin either cases or controls. CONCLUSION: The prevalence of intraprostatic inflammation was higher in the finasteride than placebo arm of the PCPT, with no association with higher-grade prostate cancer. IMPACT: Finasteride may attenuate the association between inflammation and higher-grade prostate cancer. Moreover, the missing link between intraprostatic inflammation and PSA suggests that finasteride may reduce inflammation-associated PSA elevation

Roundtable debate: Controversies in the management of the septic patient – desperately seeking consensus

Despite continuous advances in technologic and pharmacologic management, the mortality rate from septic shock remains high. Care of patients with sepsis includes measures to support the circulatory system and treat the underlying infection. There is a substantial body of knowledge indicating that fluid resuscitation, vasopressors, and antibiotics accomplish these goals. Recent clinical trials have provided new information on the addition of individual adjuvant therapies. Consensus on how current therapies should be prescribed is lacking. We present the reasoning and preferences of a group of intensivists who met to discuss the management of an actual case. The focus is on management, with emphasis on the criteria by which treatment decisions are made. It is clear from the discussion that there are areas where there is agreement and areas where opinions diverge. This presentation is intended to show how experienced intensivists apply clinical science to their practice of critical care medicine

Revolution and the end of history: Caryl Churchill's Mad Forest

Caryl Churchill’s Mad Forest, written and performed very soon after the Romanian revolution in 1990 and performed both in London and Bucharest, is a dynamic, inter-cultural play that represents a variety of perspectives on the revolutionary events, as well as oscillating between English and Romanian cultural and language coordinates. It has a peculiar topicality in its detailed and specific usages of different aspects of the revolutionary narrative, its sketches of family life before and after the revolution, and the inclusion of the revolution as reported in quasi-documentary-style testimony. The perspective in this article is one that places the play within a framework that thinks through Mad Forest’s relationship to the triumphant, neoliberalist heralding of “the end of history,” most famously argued by Francis Fukuyama in his 1989 article of that name. This discourse gained further confidence from the collapse of Eastern Europe, a collapse that was viewed by proponents of the end-of-history argument as signalling the permanent disintegration of communism and a victory for capitalism. However, Mad Forest is considered here as a play that reflects multiple perspectives on the revolutionary period and, while declining to provide political solutions as such, simultaneously refuses to accede to the implications of the end-of-history argument